Sample Legal Cognitive Capacity Report
This is a sample of a legal cognitive capacity report that can be provided for medical-legal review and litigation support, as requested. Each report can be tailored to your needs. We can provide reports for legal, clinical, or peace-of-mind needs.
Expert Clinical Medication Audit & Impact Analysis
1. Scope of Review & Materials Examined
This audit evaluates causation and contributing factors regarding cognitive decline, sedation, and fall risk in Angela Vance. Analysis is based strictly on historical records provided:
- Pharmacy Dispensing Records (01/2025 – 10/2026)
- Primary Care Visit Notes & Diagnoses (05/12/2026)
- Caregiver Symptom & Incident Logs (09/2026 – 10/2026)
2. Objective Pharmacologic Findings
Prescribed Donepezil 10mg
(Increases Acetylcholine)
← Antagonism →
OTC Diphenhydramine / Tylenol PM
(Blocks Acetylcholine)
▼ Net Result: Cognitive Impairment, Delirium, Severe Fall Risk
- Pharmacological Drug Interaction / Opposing Therapies: A clear mechanism of antagonism exists between prescribed Donepezil and self-administered/provided OTC Diphenhydramine. Diphenhydramine is classified as a potent anticholinergic agent (ACB Score = 3). Standard geriatric standard of care (AGS Beers Criteria®) explicitly advises avoiding potent anticholinergics in patients with cognitive impairment due to high risk of precipitating acute delirium and accelerating dementia symptoms.
- Additive Central Nervous System Depression: Concurrent use of a Schedule IV Benzodiazepine (Lorazepam) alongside sedating antihistamines establishes an additive central nervous system depressant effect, providing an objective pharmacological rationale for gait instability, psychomotor slowing, and subsequent fall hazards.
- Duration of Exposure: Records indicate concurrent exposure spans approximately 120 days prior to audit date.
3. Key Findings Matrix for Evidentiary Support
| Clinical Issue | Causative Agent(s) | Recognized Standard / Literature | Impact on Patient Functioning |
|---|---|---|---|
| Cognitive Decline / Confusion | Diphenhydramine + Donepezil | AGS Beers Criteria® (2023); ACB Scale | Acute intellectual impairment; therapeutic failure of dementia treatment |
| Sedation & Gait Instability | Lorazepam + Diphenhydramine | FDA Black Box Warnings; AGS Beers Criteria® | Elevated fall risk; drowsiness; impairment of activities of daily living (ADLs) |
| Nocturnal Fall Hazard | Nighttime HCTZ Dosing | Standard Geriatric Pharmacotherapy | Induced nocturia leading to unassisted night walking in an impaired state |
4. Expert Opinion Summary
Within a reasonable degree of clinical pharmacological certainty, the combination of unmonitored OTC anticholinergic sleep aids with prescribed benzodiazepine and cholinesterase inhibitor therapy created a foreseeable, drug-induced state of cognitive clouding and motor instability that significantly increased the risk of adverse events (falls and delirium).
Ready to sign up for a consultation?